Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national
7
×
national blog main
national top stories
7
×
new york top stories
san francisco top stories
biotech
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
amgen
clinical trials
cancer
europe top stories
merck
novartis
purdue pharma
roche
biogen
bristol-myers squibb
diagnostics
drug pricing
europe blog main
What
drug
7
×
bio
new
patients
roundup
cancer
fda
market
medicine
plan
pricing
acquisitions
advanced
advantages
anathema
approved
arrival
atrophy
awaited
award
bar
biggest
brings
build
buy
ceo
cholesterol
company’s
daily
daniel
data
death
debut
decades
democrat
dems
details
drugs
dyne’s
eisai
Language
unset
7
×
Current search:
drug
×
unset
×
" national top stories "
×
national
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)